Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.
Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe website has removed several links related to rare diseases and clinical trials, including specific disease pages and resources from Dailymed and NIH, which may impact access to important medical information.SummaryDifference3%
- Check36 days agoChange DetectedNew resources have been added, including links to rare disease information, drug information for Irinotecan and Pembrolizumab, and clinical trial documentation, which may be of particular interest to researchers and healthcare professionals.SummaryDifference0.3%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference3%
- Check50 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.